Telehealth company Teladoc Health (NYSE: TDOC) has been one of Wall Street's scariest roller coasters over the past three years. After it rocketed more than 700% during the height of the COVID-19 pandemic, the stock fell to almost 90% from its high; I have whiplash writing this.

The stock is now a comeback story or on a path to zero, depending on who you ask. Here we'll see why the truth falls somewhere in the middle and what investors can expect from the stock moving forward.

You can trace Teladoc's painful plunge to two primary problems facing the company. First, it paid an enormous $18.5 billion price tag to acquire medical technology company Livongo in late 2020. The addition of Livongo was supposed to be what Teladoc needed to offer a full suite of digital healthcare services that ranged from medical consultations to remote management of chronic conditions.

Continue reading

Source Fool.com